TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA a Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. EP Europace. Oxford: Oxford University Press, 2021, roč. 23, č. 4, s. 539-547. ISSN 1099-5129. Dostupné z: https://dx.doi.org/10.1093/europace/euaa261.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation
Autoři TABORSKY, Milos (203 Česká republika), Ladislav DUŠEK (203 Česká republika), Josef KAUTZNER (203 Česká republika), Marek VICHA (203 Česká republika), Renata AIGLOVA (203 Česká republika), Vit GLOGER (203 Česká republika), Marian FEDORCO (203 Česká republika), Jaroslav DUBA (203 Česká republika), Lukas DUSEK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Monika BEZDEKOVA (203 Česká republika) a Tomas SKALA (203 Česká republika, garant).
Vydání EP Europace, Oxford, Oxford University Press, 2021, 1099-5129.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.486
Kód RIV RIV/00216224:14110/21:00121729
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1093/europace/euaa261
UT WoS 000644500900009
Klíčová slova anglicky Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 8. 6. 2021 11:04.
Anotace
Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.
VytisknoutZobrazeno: 11. 5. 2024 16:26